Xponance LLC Purchases 3,251 Shares of Stryker Corporation $SYK

Xponance LLC boosted its position in Stryker Corporation (NYSE:SYK) by 5.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 63,177 shares of the medical technology company’s stock after buying an additional 3,251 shares during the quarter. Xponance LLC’s holdings in Stryker were worth $22,205,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in SYK. Czech National Bank increased its holdings in shares of Stryker by 3.9% during the fourth quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock valued at $31,898,000 after acquiring an additional 3,366 shares in the last quarter. Davis R M Inc. increased its holdings in shares of Stryker by 1.8% during the third quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock valued at $51,285,000 after acquiring an additional 2,512 shares in the last quarter. Kepler Cheuvreux Suisse SA bought a new position in shares of Stryker during the third quarter valued at $27,952,000. Daymark Wealth Partners LLC increased its holdings in shares of Stryker by 436.0% during the fourth quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock valued at $16,119,000 after acquiring an additional 37,307 shares in the last quarter. Finally, Wealthcare Advisory Partners LLC increased its holdings in shares of Stryker by 265.2% during the fourth quarter. Wealthcare Advisory Partners LLC now owns 9,328 shares of the medical technology company’s stock valued at $3,278,000 after acquiring an additional 6,774 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 323,264 shares of company stock valued at $100,659,489. Insiders own 4.60% of the company’s stock.

Stryker Trading Down 1.0%

Shares of NYSE:SYK opened at $305.82 on Friday. The stock has a market capitalization of $117.24 billion, a price-to-earnings ratio of 35.40, a PEG ratio of 1.95 and a beta of 0.78. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The stock’s 50-day simple moving average is $316.75 and its two-hundred day simple moving average is $344.20. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the business posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts expect that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on SYK shares. Jefferies Financial Group restated a “buy” rating and set a $465.00 price target on shares of Stryker in a report on Wednesday, March 4th. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. The Goldman Sachs Group restated a “neutral” rating and set a $361.00 price target on shares of Stryker in a report on Friday, May 1st. UBS Group reduced their price objective on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a report on Tuesday, March 17th. Finally, Citigroup reduced their price objective on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $395.33.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.